Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X:
”Press release from monarchE: At the 7-year analysis, adjuvant abemaciclib significantly improved overall survival. Something we rarely see in the early-stage setting and which further reinforces the role of adjuvant CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer.”
More posts featuring Paolo Tarantino.